With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...

In the latest close session, Pfizer (PFE) was up +1.51% at $25.62. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow saw a downswing of 0.37%, while the ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation. Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry.

We upgraded the rating for Pfizer (PFE) stock, ... I don't think Pfizer performance improvement is adequate when comparing against SP500. Reply. Like. Robert Hutten. 28 Aug. 2024.

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $149.8 billion, the company offers ...

Pfizer and S&P 500 Performance During 2007-08 Crisis. PFE stock declined from nearly $12 in September 2007 (pre-crisis peak) to $7 in March 2009 (as the markets bottomed out), implying it lost 45% ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter ...